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Abstract
Objectives: To use primed infusions of the magnetic resonance imaging (MRI) contrast agent Gd.DTPA (Magnevist), to
achieve an equilibrium between blood and tissue (eqMRI). This may increase tumor Gd concentrations as a novel cancer
imaging methodology for the enhancement of small tumor nodules within the low signal-to-noise background of the lung.
Methods: A primed infusion with a delay before equilibrium (eqMRI) of the Gd(III) chelator Gd.DTPA, via the intraperitoneal
route, was used to evaluate gadolinium tumor enhancement as a function of a bolus injection, which is applied routinely in
the clinic, compared to gadolinium maintained at equilibrium. A double gated (respiration and cardiac) spin-echo sequence
at 9.4T was used to evaluate whole lungs pre contrast and then at 15 (representative of bolus enhancement), 25 and 35
minutes (representative of eqMRI). This was carried out in two lung metastasis models representative of high and low tumor
cell seeding. Lungs containing discrete tumor nodes where inflation fixed and taken for haematoxylin and eosin staining as
well as CD34 staining for correlation to MRI.
Results: We demonstrate that sustained Gd enhancement, afforded by Gd equilibrium, increases the detection of
pulmonary metastases compared to bolus enhancement and those tumors which enhance at equilibrium are sub-millimetre
in size (,0.7 mm2) with a similar morphology to early bronchoalveolar cell carcinomas.
Conclusion: As Gd-chelates are routinely used in the clinic for detecting tumors by MRI, this methodology is readily
transferable to the clinic and advances MRI as a methodology for the detection of small pulmonary tumors.
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Introduction
Lung cancer is the commonest cause of cancer death worldwide
with 152,000 deaths each year in the US (NCI 2011). Accurate
and cost effective screening methods for lung cancer are
desperately needed. Screening should be sensitive to small nodules,
specific to the disease, able to detect suitability of patients for
radical treatments and be non-invasive. Prior screening trials with
chest radiographs have not found a reduction in lung cancer
mortality [1,2,3]. Computer tomography (CT) is more sensitive
than chest radiography and has recently been shown to be effective
at reducing lung cancer mortality, although the feasibility and cost
effectiveness of mass CT screening is still disputed [4,5,6]. CT
imaging can detect pulmonary nodules as small as 2 to 3 mm, but
current guidelines deem these small lesions clinically insignificant
[7]. It also lacks the specificity to distinguish between benign and
cancerous tumors, and nodules of 4 to 10 mm are followed up by
repeated CT scans thereby increasing radiation burden [8].
Positron emission tomography (PET) with fluorodeoxyglucose is
superior to CT in differentiating between malignant and benign
tumors [9,10]. Preoperative use of PET has led to a reduction in
the number of unnecessary thoracotomies in patients considered to
be operable on the basis of CT criteria [11,12]. However PET has
a low spatial resolution and reduced specificity for nodules smaller
than 10 mm [13]. Further, specificity of PET in nodules larger
than 10 mm can fall as low as 60% [14].
Magnetic resonance imaging (MRI) offers distinct advantages
over both CT and PET as it uses non-ionising radiation and has
better anatomical resolution in most tissues [15]. Lung imaging
however is challenging for MRI, due to its low tissue density, many
air-tissue interfaces, as well as respiratory and cardiac motion
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artefacts, and thus it has not reached mainstream clinical use
[16,17].
Gadolinium(III) (Gd) chelates have been widely used to detect
and investigate functional tumor perfusion by MRI in other organs
[18,19]. Gd-chelates are small molecules with short half lives,
which leak out of capillaries into the interstitial space. Tumor
blood vessels are a chaotic network of thin-walled leaky vessels
leading to increased accumulation and retardation of wash out of
Gd within viable tumor tissue termed the enhanced permeability
and retention (EPR) effect [20,21]. As Gd-chelates are normally
given as a single bolus, poorly vascularised tumors such as very
small pre-angiogenic tumors may have limited enhancement [22].
However, studies combining bolus with subsequent infusion show
that Gd concentrations in tissues of differing permeabilities can be
increased [23]. Although the use of gadolinium for dynamic
contrast enhancement (DCE) has had limited use in lung tumor
imaging [24], it is conceivable that using a primed infusion, an
equilibrium of Gd concentration between the vasculature and the
interstitial spaces can be reached and sustained. This technique
has been termed eqMRI and has been utilised to image
myocardial fibrosis in humans [25], as well as systemic amyloidosis
in preclinical murine models [26]. We hypothesised this technique
may therefore improve the imaging of small lung tumors where
equilibrium can provide continuous high concentrations of Gd
enhancement.
In this study, primed infusions with a delay before equilibrium
(eqMRI) of the Gd(III) chelator Gd.DTPA (Magnevist) were used
to evaluate gadolinium tumor enhancement as a function of a
bolus injection, which is applied routinely in the clinic, compared
to gadolinium maintained at equilibrium. This was carried out in
two lung metastasis models representative of high and low tumor
cell seeding. We demonstrate that eqMRI specifically improves the
detection of small pulmonary metastases compared to bolus
enhancement. This methodology would be readily transferable to
the clinic using a similar strategy to that used by Flett A.S. et al. in
humans [25] and advances MRI as a methodology for the
detection of small primary or metastatic tumors.
Materials and Methods
Tissue Culture
Cells were grown in T175 flasks (Fisher Scientific, Loughbor-
ough, UK) in Dulbecco’s Modified Eagles Medium (DMEM)
(Invitrogen, Paisley, UK), supplemented with 10% heat inactivat-
ed fetal calf serum (GIBCO, Grand Island NY, USA) in a
humidified incubator at 37uC with 95% air, and 5% CO2.
Lentiviral Production and Cell Transduction
Lentivirus vectors pseudotyped with the vesicular stomatitis G
protein (VSV-G) were generated by transfection into 293T human
kidney cells (ATCC) of a packaging construct (pCpr-ENV), a
plasmid producing the VSV-G envelope (pVSV-G) and the vector
encoding yellow fluorescent protein (YFP) and the luciferase gene
(Luc) (pLIONII-HYG-Luc2YFP) as described previously [27].
Plasmid vectors were kindly provided by Dr S Goldie (Cancer
Research Institute, CRUK, Cambridge UK). Conditioned medi-
um was harvested at 24 hours and passed through 0.45 mm filters.
The transduction of non-confluent MDA-MB-231 cells (CRUK)
in a T175 flask was performed using 4 mg/ml polybrene (20 ml
polybrene with 20 ml virus in 20 ml medium). The lentivirus was
left for 48 hours before changing media. 24 hours later the
presence of YFP was assessed by fluorescent microscopy. As the
luciferase lentivirus contains a hygromycin resistance gene,
200 mg/ml Hygromycin B was added to culture media for 48
hours. Cells were found to be 96% transfected by flow cytometry
using a FACS Calibur (Becton Dickinson, Franklin Lakes NJ,
USA).
Animal Model
All animal studies were approved by the University College
London Biological Services Ethical Review Committee and
licensed under the UK Home Office regulations and the Guidance
for the Operation of Animals (Scientific Procedures) Act 1986
(Home Office, London, United Kingdom). Animal weights were
recorded every two days and tumor monitoring was carried out
weekly by bioluminescence and MRI scanning with animal
monitoring equipment. All procedures were carried out under
breathing anaesthesia. Mice were sacrificed with 200 ml pento-
barbital by intraperitoneal (i.p) injection (200 mg/ml) and death
was confirmed by exsanguination prior to lung inflation (see
histology). Male NOD SCID gamma (NSG) mice, 6–8 weeks,
were anaesthetised using 2% isoflurane and the tail vein
cannulated for infusion of cells. Mice either received a high
seeding of cells (26106 cells in 200 ml serum free media, n= 6, 3
eqMRI & 3 high dose) to achieve rapid growing multiple
metastases for weekly longitudinal evaluation, or a low seeding
of cells (16105 cells in 200 ml serum free media, n= 3) to produce
slower growing discrete nodules. These low seeding tumors were
taken for histology as soon as they were identified by MRI.
Control mice received no cells. Mice were imaged using
bioluminescence directly after injection and then by both
bioluminescence and MRI at weekly time points.
Bioluminescence Imaging
Mice were anesthetized with 2% isoflurane before and during
imaging. An aqueous solution of D-luciferin (Regis Technologies
Inc, Morton Grove, IL, USA) at 150 mg/kg in a volume of 200 ml
was injected i.p 10 minutes before imaging. Imaging was
performed using an IVISH Lumina II bioluminescent scanner
(Caliper Life Sciences, Hopkinton, MA, USA). Quantification of
the bioluminescent signal was performed using a region of interest
(ROI) covering the whole thorax using Living Image software
(version 4: Caliper Life Sciences).
eqMRI
Mice were anesthetized with 2% isoflurane before and during
imaging. Two i.p lines were used to administer either a bolus or an
infusion of Gd.DTPA (MagnevistH, Schering, Berlin). Although,
the kinetics of intravenous and i.p injection is different once
equilibrium is reached the steady state is the same [26]. For this
purpose the i.p route is more suitable and the dosing has been
based on the late Gd i.p mouse dose described by Price A.N
et al.2011 [28] with the subsequent infusion half the bolus dose
over 1 hour as described for eqMRI by Campbell A.E et al. 2011
[26]. Imaging was performed on an Agilent 9.4T scanner (Agilent
Technologies. Santa Clara, CA, USA) with a 39 mm coil (RAPID
Biomed, Rimpar, Germany) using a multi-slice double gated
(respiration and cardiac) spin-echo sequence with the following
parameters: TR , 3.6 s (between RF TR 120–150 ms) deter-
mined by gating and number of slices (breathing rate , 50
breaths/minute, and heart rate 400–500 beats/minute),
TE=9.6 ms, FOV=30630 mm (363 cm), averages = 1: matrix
size = 2566128, slices = 10, thickness = 1 mm. Scan time , 8
minutes. After the initial pre contrast scan, mice were given a bolus
of 0.6 mmol/kg Gd.DTPA (prime) and after 15 minutes an
infusion of 0.005 mmol/kg/min Gd.DTPA was started. Images
were acquired directly after the infusion was started at 15 minutes,
synonymous with tumor enhancement from the bolus only
Gd.DTPA Equilibrium MRI Detects Small Lung Tumors
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(preliminary bolus experiments showed this to be the maximal
enhancement in subcutaneous tumors via i.p). Images were
acquired again at both 25 and 35 minutes, equivalent to tumor
enhancement caused by Gd equilibrium in normal tissues
(Figure 1). This methodology of bolus with delayed infusion allows
for direct comparison of tumor enhancement following bolus
compared to equilibrium.
eqMRI vs High Dose
To assess if tumor enhancement at 25 minutes onwards was due
to Gd equilibrium and not just the increased dose of Gd, the total
dose of Gd.DTPA for eqMRI was given as a single bolus dose
(high dose) in three mice at day 14 (high tumor seeding mice) and
compared to eqMRI at the same imaging time points (Figure 1).
MRI Data Analysis
Signal-to-noise (Figure S1). All images were analysed using
ImageJ (Rasband, ImageJ, U.S. National Institutes of Health,
Bethesda, Maryland, USA, http://rsb.info.nih.gov/ij/, 1997–
2008). Signal-to-noise ratios (SNR) for control lung were obtained
from a ROI from whole lung (excluding major vessels) at each
time point. To assess the enhancement in individual tumors, ROIs
for SNR were drawn around a discrete lesion at the first point of
tumor visualisation and then loaded onto the corresponding pre or
post images to give the SNR time course for each tumor. Tumors
were classed into two; either visible (detected without Gd) or
enhancing (detectable after Gd only). In the low tumor cell seeding
model, each mouse had one enhancing tumor (n= 3) and at least
one visible tumor (n= 5) and a two-sample equal variance t-test
was used. Whereas, in the high tumor cell seeding model, three
enhancing and three visible tumors were chosen from each mouse
(n = 9). Therefore a two-tailed paired t-test assuming equal
variances was performed at each time point to determine
significant difference, at the 5% level statistical significance.
Tumor volume measurements (Figure S2). To assess the
increase in visualized tumors by Gd enhancement, an ROI was
drawn around the whole lung (excluding major vessels) on each
slice and the total lung volume calculated. As the signal intensity
(SI) values of control lung were low, SI values above this threshold
were deemed as either tumor or normal enhancing tissue. A
threshold was applied from the highest SI value of control lung
and the volume of the remaining tissue calculated as a percentage
of the total lung volume. To account for the normal enhancing
tissue the value obtained from control lung was subtracted from
this as a correction value. The resulting volume left is therefore
that of tumor and is termed the ‘‘percentage lung tumor volume’’.
To assess if Gd equilibrium increased the number of tumors visible
compared to bolus, the percentage lung tumor volume at 15, 25
and 35 minutes was divided by the pre contrast volume and
expressed as a percentage increase, termed as the ‘‘percentage
increase in observed tumors’’. A similar approach to assessing lung
tumor burden has been described by Tidwell V.K et al. 2012 [29].
A two-tailed paired t-test assuming equal variances was performed
at each time point to determine significant difference (n = 3 per
group), at the 5% level statistical significance. Errors are given as
standard errors of the mean (s.e.m) for both SNR and the
percentage increase in observed tumors.
Histology
Inflated lungs were fixed in 4% formalin for 4 hours at 4uC and
then incubated overnight in 15% sucrose in PBS at 4uC. Tissue
was dehydrated in 70% ethanol and embedded in paraffin.
Sections corresponding to MR images were cut at 5 mm. Sections
were stained with either Haematoxylin (Sigma-Aldrich, Dorset,
UK) for 1 minute and Eosin (Sigma-Aldrich, UK) for 30 seconds
(H & E), or by CD34 immunohistochemistry. Immunohistochem-
istry, including antigen retrieval and signal amplification was
carried out as previously described [30]. Antibodies for CD34
detection were as follows; rat anti-mouse primary CD34 antibody
at a 1:5 dilution (Hycult Biotech, The Netherlands), biotinylated
secondary antibody at a 1:200 dilution (Dako, Denmark).
Immunoreactions were visualized using diaminobenzidine hydro-
chloride (DAB Substrate Kit, Vector Laboratories) as chromogen.
Sections were counterstained with haematoxylin as above. Images
were obtained using an Olympus BX40 microscope (Olympus
Imaging, Essex, UK) with Qcapture software (QImaging, Cana-
da). Composite images of whole lungs were made from multiple
single 100x images using Adobe Photoshop CS (Adobe Systems
Inc, California, USA). Tumors were sized by histology at the
widest midpoint on H & E stained slides by Qcapture software
rather than by MRI due to partial volume and susceptibility effects
that can over estimate tumor size.
Results
Two models of lung metastasis representative of high and low
tumor cell seeding were evaluated by eqMRI (Figure 1, experi-
mental dosing plan). Animals in the high tumor cell seeding model
were followed weekly longitudinally up until day 28, these animals
appeared healthy and recovered well at all time points after
imaging (n= 3). Animals receiving low tumor cell seeding,
generating discrete tumor nodules were taken for histology as
soon as they were identified by MRI (n= 3). Bioluminescence
Figure 1. Experimental plan showing timings of bolus and infusion as well as scan times. The bars above are an assumed grey scale
representation of gadolinium concentration within the blood where black is high and white low concentration.
doi:10.1371/journal.pone.0054903.g001
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confirmed tumor growth in both models prior to identification by
MRI (Figures S3 and S4). The SNR was used to assess the
enhancement in individual tumors, while the increase in the
volume of tumors becoming visible after Gd enhancement was
expressed as the ‘‘percentage increase in observed tumors’’.
Control lungs did not show any contrast enhancement throughout
eqMRI (Figure 2A) (SNR was 1.6860.57 at pre contrast and
constant throughout p = 0.25, n= 3).
Gd.DTPA Sustained at Equilibrium Improves the
Detection of Pulmonary Tumors Compared to Bolus
Enhancement
Lung metastases were detectable in animals receiving high
tumor cell seeding as areas of hyperintensity from day 14, and
from day 21 in low tumor cell seeding animals. eqMRI imaging
defined two sets of tumors. Tumors visible on pre contrast images
that did not change in presentation and their SNR values
remained constant at all time points are termed as visible tumors
(Figure 2 white arrowheads, Figure 3A). Tumors that only became
visible with Gd enhancement at 15, 25 or 35 minutes but were not
apparent on the pre scan image are termed enhancing tumors
(Figure 2 white arrows). All high tumor cell seeding mice presented
with multiple visible and enhancing tumors (n = 9 each). Whereas,
low tumor cell seeding mice exhibited at least one visible (n = 5)
and one enhancing tumor (n = 3) by MRI prior to histology. As the
mice in the low tumor cell seeding model were taken as soon as
tumors were visible by MRI for histology, this limited the numbers
of tumors per mouse that could be assessed. Although the trends in
Gd enhancement are similar for both models this needs to be
taken into account. Also, the number of mice per group (n = 3) is a
limiting factor when evaluating the percentage increase in
observed tumor data.
Although a few diffuse tumors become evident at 15 minutes
(Figure 2D 15 minutes, arrows) after the initial bolus prime, the
majority of enhancing tumors were observed due to sustaining Gd
equilibrium at 25 minutes onwards (Figure 2B and D, arrows).
This is also evident in the rise in SNR in individual tumors from
pre contrast compared to 15 minutes (p =,0.05) with a further
increase at 25 minutes which was sustained at 35 minutes
(p =,0.05) (Figure 3B and Figure S5B). eqMRI resulted in an
significant increase in the percentage observed tumors at Gd
equilibrium compared to bolus (p =,0.05) (Figure 3C and Figure
S5C). Although in the low tumor cell seeding model there is an
increase in the percentage observed tumors at 35 minutes
compared to 25 minutes (Figure 3C), for the high tumor cell
seeding model there is a reduction at 35 minutes compared to 25
minutes (Figure 4C & Figure S5C). This is most likely due to the
amount of Gd accumulating within the tumors leading to
susceptibility artefacts and T2* affects, which is more apparent
in high tumor cell seeding model.
Gd.DTPA at Equilibrium not the Dose Improves
Pulmonary Tumor Detection
When a bolus dose of Gd.DTPA equivalent to the total dose of
Gd.DTPA used in eqMRI was given as single bolus, animals did
Figure 2. MR images over the 35 minute eqMRI time course. A) control lungs, B) a discrete gadolinium enhancing tumor nodule (25 minutes)
(low tumor cell seeding model), C) tumor nodules visible on the pre contrast scan (low tumor cell seeding model), D) tumor presentation
representative of a high tumor cell seeding model lung at day 14. Tumors visible on pre contrast (white arrowheads) and tumors only visible with
gadolinium enhancement (white arrows) are indicated.
doi:10.1371/journal.pone.0054903.g002
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not present late enhancing tumors at 25 or 35 minutes (Figure 4A).
Tumors visible on the pre contrast remained unchanged as in
eqMRI (Figure 4A, white arrows). The percentage increase in
observed tumors for both eqMRI and high dose Gd.DTPA was
the same at 15 minutes (Figure 4B). Although, the high dose would
be expected to increase the percentage observed tumors compared
to the lower dose used in eqMRI at this time point, there appears
to be no effect. This may be due to intergroup heterogeneity, but
as fewer enhancing tumors appear to be present in the high dose
this may indicate that any enhancing tumors are saturated with
Gd causing susceptibility and T2* effects as described previously
affecting visualization. As the bolus has a limited time window for
enhancement compared to Gd at equilibrium there is no further
enhancement at 25 and 35 minutes for the high dose and the
percentage increase in observed tumors is therefore significantly
higher for eqMRI than the high bolus dose at these time points,
confirming the contribution of Gd equilibrium to lung tumor
enhancement (Figure 4B).
Gd Equilibrium Enhancing Tumors are Sub-millimeter in
Size
Histology examination of lung sections corresponding to MR
images for low tumor cell seeding mice, showed that tumors
enhancing at 25 minutes onwards due to Gd equilibrium were
sub-millimeter (,0.7 mm2) tumors (Figure 5A), whereas tumors
visible on pre contrast images tended to be larger (Figure 5B).
Occasionally, visible tumors were also sub-millimeter in size and
histology showed these as solid tumors (Figure 5D and E).
Enhancing tumors however, appeared to line and fill the avelolar
spaces with similar morphology to that shown by early
bronchoavelolar cell carcinomas and atypical adenomatous
hyperplasia (Figure 5C). Longitudinal evaluation of enhancing
tumors showed that with tumor growth they become visible on the
pre contrast scan further confirming them as tumors (Figure S6
white arrow at day 14 and subsequent white arrow head at day
21).
Discussion
In this study, primed infusions with a delay in equilibrium
(eqMRI) of Gd.DTPA were used to compare gadolinium tumor
enhancement of pulmonary tumors after bolus (as routinely used
in the clinic), or gadolinium maintained at equilibrium. The results
show that the maximal enhancement of pulmonary tumors was
due to sustained Gd enhancement afforded by Gd equilibrium (25
minutes onwards) in both lung metastasis models. As few tumors
enhanced after the high dose bolus prime (15 minutes), without Gd
equilibrium the majority of enhancing tumors in this study would
have been missed with a traditional Gd bolus MRI protocol.
Histological examination confirmed that the Gd equilbrium
enhancing tumors were small (,0.7 mm) disorganised tumors with
a low cellularity. The tumor cells line and fill the avelolar spaces in
a similar manner to early bronchoavelolar cell carcinomas. The
low cellular density means that they are not evident on the pre
contrast scan and as the tumors are integrated within the avelolar
spaces this increases the degree of diffusion of Gd.DTPA into the
tumor interstitial spaces [31,32,33,34]. Gd equilibrium is therefore
able to increase the concentration of Gd sufficiently, making them
visible by MRI.
Both lung metastasis models presented with tumors that were
already visible on pre contrast images. These tumors showed no
significant contrast enhancement with Gd. Although, histological
examination showed that they are generally larger than enhancing
tumors, visible tumors could still be sub-millimeter in size. The
Figure 3. Low tumor cell seeding model mean values for signal-
to noise (SNR) and the percentage increase in observed
tumours for eqMRI. A) SNR of tumors already visible on pre contrast
images, B) SNR of tumors that were visible due to Gd enhancement
from 15 minutes onwards, C) the percentage increase in observed
tumors by Gd enhancement at each time point compared to pre
contrast. Values are mean 6 s.e.m. * p =,0.05 from pre (A and B) or
from 15 min (C).
doi:10.1371/journal.pone.0054903.g003
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Figure 4. MR images of a high tumor cell seeding model mouse at day 14 over the 35 minutes for high dose Gd.DTPA (white
arrowsheads denote visible tumors) (A), and the corresponding mean values for the percentage increase in observable tumors
compared to that of high tumor cell seeding mice at day 14 for eqMRI (B). Values are mean 6 s.e.m. * p =,0.05 from high dose.
doi:10.1371/journal.pone.0054903.g004
Figure 5. An MR image of a low tumor cell seeding model mouse lung the corresponding whole lung composite H & E stained
section, a blown up area and sizing of tumor (white box), and CD34 immunohistochemistry image. A) a single enhancing tumour (at 25
minutes) with corresponding CD34 image (C), B) two visible tumors (pre contrast image) with corresponding CD34 images left (D) and right (E).
doi:10.1371/journal.pone.0054903.g005
Gd.DTPA Equilibrium MRI Detects Small Lung Tumors
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main difference, except for size, appears to be that they have a
higher cell density than the enhancing tumors, which may account
for the early visualisation on MRI.
A previous study by Garbow et al. used a similar breathing gated
sequence and detected lung tumor nodules in mice at a
comparable size to the small visible tumors shown in this study
[35]. Although the study did not investigate Gd enhancement, it
verifies the use of MRI in the detection of sub-millimetre
metastases. Other methods for lung metastasis imaging utilizing
MRI such as Ultra-short echo time (UTE) imaging [36,37,38,39],
fluorinated [40] or paramagnetic molecular oxygen [41] and most
recently hyperpolarised 129Xe and 3H gas [42,43,44,45] have also
been developed. A recent study by Branca et al. has combined
hyperpolarized gas with tumor targeted iron oxide particles
enhancing the detection of tumors at sub-millimetre sizes [46].
The gadolinium doses used in this study have been designed for
the preclinical identification of small pulmonary metastases in
mouse models of lung metastasis due to Gd given as a bolus or Gd
maintained at equilibrium. The doses are therefore much higher
than what would be used in the clinic. Although, this is a
limitation, gadolinium can be maintained at equilibrium in
humans at much lower doses and eqMRI has already been
utilized in humans to assess myocardial fibrosis [25]. Although the
use of this dosing regimen for the imaging of small pulmonary
tumors would require further optimization, this methodology has
the potential to be a safe and sensitive method for the detection of
small primary or metastatic tumors in a similar fashion to CT. The
dynamic uptake of Gd-chelates has been shown to improve the
discrimination of benign and malignant tumors in other tissues
types screening [47]. However, this has not been assessed in this
study using eqMRI.
In conclusion, the results for this study demonstrate that a high
concentration of sustained Gd enhancement afforded by eqMRI
greatly improves the detection of sub-millimetre pulmonary
metastases. The diffusion of contrast throughout the tumor mass
increases the concentration of Gd retained causing enhancement
when Gd equilibrium is reached.
Supporting Information
Figure S1 Flow diagram describing how the two sets of
tumors were defined and how regions of interests where
placed for individual tumor signal-to-noise calculations
(see MRI data analysis). Drawn ROIs are only representative
for explanation purposes.
(TIF)
Figure S2 Flow diagram describing how tumor volumes
were calculated to assess the percentage increase in
observed tumors due to Gd enhancement (see MRI data
analysis).
(TIF)
Figure S3 Bioluminescent images of a high tumor cell
seeding model mouse directly after infusion and at days
7 and 14 (A) and the corresponding plot of increasing
bioluminescent signal (B) consistent with tumor growth.
(TIF)
Figure S4 Bioluminescent images of a low tumor cell
seeding model mouse directly after infusion and weekly
to 35 days (A) and the corresponding plot of increasing
bioluminescent signal (B) consistent with tumor growth.
(TIF)
Figure S5 High tumor cell seeding model weekly mean
values for signal-to noise (SNR) and the percentage
increase in observed tumours for eqMRI. A) SNR of
tumors already visible on pre contrast images, B) SNR of tumors
that were visible due to Gd enhancement from 15 minutes
onwards, C) the percentage increase in observed tumors by Gd
enhancement at each time point compared to pre contrast. Values
are mean6 s.e.m. * p=,0.05 from pre (A and B) or from 15 min
(C).
(TIF)
Figure S6 MR images over the 35 minute eqMRI time
course for a high tumor cell seeding model mouse at day
14 (top row), and day 21 (bottom row). Tumors that
enhance due to gadolinium equilibrium (white arrow) at day 14,
subsequently due to tumor growth are then visible on the pre
contrast image (white arrowheads) at day 21.
(TIF)
Author Contributions
Conceived and designed the experiments: TLK AEC-W BMS ANP SW-S
SMJ MFL. Performed the experiments: TLK AEC-W ES KLO. Analyzed
the data: TLK AEC-W MFL. Contributed reagents/materials/analysis
tools: TLK ES BMS ANP SW-S. Wrote the paper: TLK SMJ MFL.
References
1. Melamed MR, Flehinger BJ, Zaman MB, Heelan RT, Perchick WA, et al.
(1984) Screening for early lung cancer. Results of the Memorial Sloan-Kettering
study in New York. Chest 86: 44–53.
2. Frost JK, Ball WC Jr, Levin ML, Tockman MS, Baker RR, et al. (1984) Early
lung cancer detection: results of the initial (prevalence) radiologic and cytologic
screening in the Johns Hopkins study. Am Rev Respir Dis 130: 549–554.
3. Fontana RS, Sanderson DR, Taylor WF, Woolner LB, Miller WE, et al. (1984)
Early lung cancer detection: results of the initial (prevalence) radiologic and
cytologic screening in the Mayo Clinic study. Am Rev Respir Dis 130: 561–565.
4. Gohagan JK, Marcus PM, Fagerstrom RM, Pinsky PF, Kramer BS, et al. (2005)
Final results of the Lung Screening Study, a randomized feasibility study of spiral
CT versus chest X-ray screening for lung cancer. Lung Cancer 47: 9–15.
5. Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, et al. (2011) Reduced
lung-cancer mortality with low-dose computed tomographic screening.
N Engl J Med 365: 395–409.
6. Spiro SG, Navani N (2012) Screening for lung cancer: is this the way forward?
Respirology 17: 237–246.
7. Kennel SJ, Davis IA, Branning J, Pan H, Kabalka GW, et al. (2000) High
resolution computed tomography and MRI for monitoring lung tumor growth in
mice undergoing radioimmunotherapy: correlation with histology. Med Phys 27:
1101–1107.
8. Patz EF, Jr., Black WC, Goodman PC (2001) CT screening for lung cancer: not
ready for routine practice. Radiology 221: 587–591; discussion 598–589.
9. Kubota K, Matsuzawa T, Fujiwara T, Ito M, Hatazawa J, et al. (1990)
Differential diagnosis of lung tumor with positron emission tomography: a
prospective study. J Nucl Med 31: 1927–1932.
10. Gupta NC, Frank AR, Dewan NA, Redepenning LS, Rothberg ML, et al. (1992)
Solitary pulmonary nodules: detection of malignancy with PET with 2-[F-18]-
fluoro-2-deoxy-D-glucose. Radiology 184: 441–444.
11. Hoekstra CJ, Stroobants SG, Smit EF, Vansteenkiste J, van Tinteren H, et al.
(2005) Prognostic relevance of response evaluation using [18F]-2-fluoro-2-deoxy-
D-glucose positron emission tomography in patients with locally advanced non-
small-cell lung cancer. J Clin Oncol 23: 8362–8370.
12. Song JW, Oh YM, Shim TS, Kim WS, Ryu JS, et al. (2009) Efficacy comparison
between (18)F-FDG PET/CT and bone scintigraphy in detecting bony
metastases of non-small-cell lung cancer. Lung Cancer 65: 333–338.
13. Gambhir SS (2002) Molecular imaging of cancer with positron emission
tomography. Nat Rev Cancer 2: 683–693.
14. Gould MK, Fletcher J, Iannettoni MD, Lynch WR, Midthun DE, et al. (2007)
Evaluation of patients with pulmonary nodules: when is it lung cancer?: ACCP
evidence-based clinical practice guidelines (2nd edition). Chest 132: 108S–130S.
15. Weissleder R (2002) Scaling down imaging: molecular mapping of cancer in
mice. Nat Rev Cancer 2: 11–18.
16. Runge VM, Wood ML (1988) Fast imaging and other motion artifact reduction
schemes: a pictorial overview. Magn Reson Imaging 6: 595–607.
Gd.DTPA Equilibrium MRI Detects Small Lung Tumors
PLOS ONE | www.plosone.org 7 January 2013 | Volume 8 | Issue 1 | e54903
17. Hatabu H, Alsop DC, Listerud J, Bonnet M, Gefter WB (1999) T2* and proton
density measurement of normal human lung parenchyma using submillisecond
echo time gradient echo magnetic resonance imaging. Eur J Radiol 29: 245–252.
18. Semelka RC, Helmberger TK (2001) Contrast agents for MR imaging of the
liver. Radiology 218: 27–38.
19. Padhani AR, Husband JE (2001) Dynamic contrast-enhanced MRI studies in
oncology with an emphasis on quantification, validation and human studies. Clin
Radiol 56: 607–620.
20. Fukumura D, Yuan F, Monsky WL, Chen Y, Jain RK (1997) Effect of host
microenvironment on the microcirculation of human colon adenocarcinoma.
Am J Pathol 151: 679–688.
21. Iyer AK, Khaled G, Fang J, Maeda H (2006) Exploiting the enhanced
permeability and retention effect for tumor targeting. Drug Discov Today 11:
812–818.
22. Padhani AR (1999) Dynamic contrast-enhanced MRI studies in human
tumours. Br J Radiol 72: 427–431.
23. Tofts PS, Berkowitz BA (1994) Measurement of capillary permeability from the
Gd enhancement curve: a comparison of bolus and constant infusion injection
methods. Magn Reson Imaging 12: 81–91.
24. Parker GJM, Clark D, Watson Y, Buckley DL, Berrisford C, et al. (2003) T1-
Weighted DCE-MRI Apllied to Lung Tumours: Pre-Processing and Modelling.
Proceedings of the 11th ISMRM Toronto: 1255.
25. Flett AS, Hayward MP, Ashworth MT, Hansen MS, Taylor AM, et al. (2010)
Equilibrium contrast cardiovascular magnetic resonance for the measurement of
diffuse myocardial fibrosis: preliminary validation in humans. Circulation 122:
138–144.
26. Campbell AE, Price AN, Ellmerich S, Simons P, Al-Shawi R, et al. (2011)
Equilibrium contrast CMR for the detection of amyloidosis in mice. JCMR
13(S1): O60.
27. Zufferey R, Nagy D, Mandel RJ, Naldini L, Trono D (1997) Multiply attenuated
lentiviral vector achieves efficient gene delivery in vivo. Nat Biotechnol 15: 871–
875.
28. Price AN, Cheung KK, Lim SY, Yellon DM, Hausenloy DJ, et al. (2011) Rapid
assessment of myocardial infarct size in rodents using multi-slice inversion
recovery late gadolinium enhancement CMR at 9.4T. J Cardiovasc Magn
Reson 13: 44.
29. Tidwell VK, Garbow JR, Krupnick AS, Engelbach JA, Nehorai A (2012)
Quantitative analysis of tumor burden in mouse lung via MRI. Magn Reson
Med 67: 572–579.
30. Aguilar S, Scotton CJ, McNulty K, Nye E, Stamp G, et al. (2009) Bone marrow
stem cells expressing keratinocyte growth factor via an inducible lentivirus
protects against bleomycin-induced pulmonary fibrosis. PLoS One 4: e8013.
31. Vaupel P, Kallinowski F, Okunieff P (1989) Blood flow, oxygen and nutrient
supply, and metabolic microenvironment of human tumors: a review. Cancer
Res 49: 6449–6465.
32. Fleming JB, Brekken RA (2003) Functional imaging of angiogenesis in an
orthotopic model of pancreatic cancer. J Cell Biochem 90: 492–501.
33. Bergers G, Benjamin LE (2003) Tumorigenesis and the angiogenic switch. Nat
Rev Cancer 3: 401–410.
34. Jain RK (2005) Antiangiogenic therapy for cancer: current and emerging
concepts. Oncology (Williston Park) 19: 7–16.
35. Garbow JR, Zhang Z, You M (2004) Detection of primary lung tumors in
rodents by magnetic resonance imaging. Cancer Res 64: 2740–2742.
36. Hatabu H, Chen Q, Stock KW, Gefter WB, Itoh H (1999) Fast magnetic
resonance imaging of the lung. Eur J Radiol 29: 114–132.
37. Togao O, Tsuji R, Ohno Y, Dimitrov I, Takahashi M (2010) Ultrashort echo
time (UTE) MRI of the lung: assessment of tissue density in the lung
parenchyma. Magn Reson Med 64: 1491–1498.
38. Takahashi M, Togao O, Obara M, van Cauteren M, Ohno Y, et al. (2010)
Ultra-short echo time (UTE) MR imaging of the lung: comparison between
normal and emphysematous lungs in mutant mice. J Magn Reson Imaging 32:
326–333.
39. Kokuryo D, Kumamoto E, Takao Y, Fujii S, Kaihara T, et al. (2012) Evaluation
of a vessel-tracking-based technique for dynamic targeting in human liver. Magn
Reson Med 67: 156–163.
40. Rinck PA, Petersen SB, Lauterbur PC (1984) [NMR imaging of fluorine-
containing substances. 19-Fluorine ventilation and perfusion studies]. Rofo 140:
239–243.
41. Edelman RR, Hatabu H, Tadamura E, Li W, Prasad PV (1996) Noninvasive
assessment of regional ventilation in the human lung using oxygen-enhanced
magnetic resonance imaging. Nat Med 2: 1236–1239.
42. Albert MS, Cates GD, Driehuys B, Happer W, Saam B, et al. (1994) Biological
magnetic resonance imaging using laser-polarized 129Xe. Nature 370: 199–201.
43. Saam BT, Yablonskiy DA, Kodibagkar VD, Leawoods JC, Gierada DS, et al.
(2000) MR imaging of diffusion of (3)He gas in healthy and diseased lungs. Magn
Reson Med 44: 174–179.
44. Salerno M, Altes TA, Mugler JP 3rd, Nakatsu M, Hatabu H, et al. (2001)
Hyperpolarized noble gas MR imaging of the lung: potential clinical
applications. Eur J Radiol 40: 33–44.
45. Driehuys B, Hedlund LW (2007) Imaging techniques for small animal models of
pulmonary disease: MR microscopy. Toxicol Pathol 35: 49–58.
46. Branca RT, Cleveland ZI, Fubara B, Kumar CS, Maronpot RR, et al. (2010)
Molecular MRI for sensitive and specific detection of lung metastases. Proc Natl
Acad Sci U S A 107: 3693–3697.
47. Fan X, Medved M, River JN, Zamora M, Corot C, et al. (2004) New model for
analysis of dynamic contrast-enhanced MRI data distinguishes metastatic from
nonmetastatic transplanted rodent prostate tumors. Magn Reson Med 51: 487–
494.
Gd.DTPA Equilibrium MRI Detects Small Lung Tumors
PLOS ONE | www.plosone.org 8 January 2013 | Volume 8 | Issue 1 | e54903
